

AM

Case: Blumberg 5
Filing Date: April 14, 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/095070 A2

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: **PCT/GB02/02345**

(22) International Filing Date: **20 May 2002 (20.05.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0112238.1 18 May 2001 (18.05.2001) **GB**

(71) Applicant (for all designated States except US): **MEDICAL BIOSYSTEMS LTD.** [GB/GB]; The Old Mill, Beaston Cross, Broadhempston, Nr- Totnes, Devon TQ9 6BX (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **DENSHAM, Daniel, Henry** [GB/GB]; The Old Mill, Beaston Cross, Broadhempston, Nr- Totnes, Devon TQ9 6BX (GB).

(74) Agent: **JAPPY, John, William, Graham**; Gill Jennings & Every, Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/095070 A2

(54) Title: **POLYNUCLEOTIDE SEQUENCING METHOD**

(57) Abstract: A method for determining the sequence of a polynucleotide comprising the steps of (i) contacting a polynucleotide processive enzyme immobilised in a fixed position, with a target polynucleotide under conditions sufficient to induce enzyme activity; (ii) detecting an effect consequent on the interaction of the enzyme and the polynucleotide, wherein the effect is detected by measurement of a non-linear optical signal or a linear signal coupled to a non-linear signal.

POLYNUCLEOTIDE SEQUENCING METHOD

Field of the Invention

This invention relates to a method for determining the sequence of a polynucleotide.

5 Background of the Invention

The ability to determine the sequence of a polynucleotide is of great scientific importance, as shown by the Human Genome Project in mapping the three billion bases of DNA encoded in the human genome.

The principle method in general use for large-scale DNA sequencing is
10 the chain termination method. This method was first developed by Sanger and Coulson (Sanger *et al.*, Proc. Natl. Acad. Sci. USA, 1977; 74: 5463-5467), and relies on the use of dideoxy derivatives of the four nucleoside triphosphates which are incorporated into the nascent polynucleotide chain in a polymerase reaction. Upon incorporation, the dideoxy derivatives terminate the polymerase
15 reaction and the products are then separated by gel electrophoresis and analysed to reveal the position at which the particular dideoxy derivative was incorporated into the chain.

Although this method is widely used and produces reliable results, it is recognised that it is slow, labour-intensive and expensive.

20 Fluorescent labels have been used to identify nucleotide incorporation onto a growing nascent DNA molecule, using the polymerase reaction (see WO91/06678). However, these techniques have the disadvantage of increasing background interference from the fluorophores. As the DNA molecule grows, the background "noise" increases and the time required to detect each nucleotide
25 incorporation needs to be increased. This severely restricts the use of the method for sequencing large polynucleotides. The most serious limitation of polynucleotide sequencing systems built around fluorescent dyes, however, is the problem of photobleaching.

Photobleaching is a well documented phenomenon in fluorescent dye
30 systems and results from exposure of the dye to excitation wavelengths. All dye systems have an ability to absorb a limited number of photons before photobleaching occurs. Once photobleaching has occurred the fluorescent dye

is no longer visible to the observer and hence, if conjugated to a molecule, this will not be detectable.

There is therefore a need for an improved method for determining the sequence of a polynucleotide, which significantly increases the rate and
5 fragment size of the polynucleotide being sequenced and which preferably does not depend on fluorescently labelled nucleotides for detection. Further, the method should be capable of being carried out by an automated process, reducing the complexity and cost associated with existing methods.

Summary of the Invention

10 The present invention is based on the realisation that a conformational and/or mass and/or energy distribution change in a polynucleotide processive enzyme, which occurs when an enzyme associates with and moves along a target polynucleotide, can be detected using non-linear optical imaging, including that based on second or third harmonic generation.

15 According to the present invention, a method for sequencing a polynucleotide comprises the steps of:

- (i) contacting a polynucleotide processive enzyme, immobilised in a fixed position, with a target polynucleotide under conditions sufficient for enzyme activity; and
- 20 (ii) detecting an effect consequent on the interaction of the enzyme and the polynucleotide, wherein the effect is detected by measurement of a non-linear optical signal or a linear signal coupled to a non-linear signal.

Numerous advantages are achieved with the present invention. Sequencing can be carried out with small amounts of polynucleotide, with the
25 capability of sequencing single polynucleotide molecules, thereby eliminating the need for amplification prior to initiation of sequencing. Long sequence read lengths can be obtained and secondary structure considerations minimised. Obtaining long read lengths eliminates the need for extensive fragment reassembly using computation. Further, as the invention is not dependent upon
30 the need for fluorescently-labelled nucleotides or any measurement of fluorescence, the limitation of read length at the single molecule level as a function of photobleaching or other unpredictable fluorescence effects, is

circumvented. The present invention also permits long polynucleotide fragments to be read sequentially by the same enzyme system. This has the benefit of allowing a single enzyme system to be used which can be regenerated and re-used allowing many different polynucleotide templates to be sequenced. Finally, 5 the utilisation of Second or Third Harmonic Generation offers advantages due to the lack of photodamage and photobleaching. This is due to the fact that no photochemistry occurs, even in the focal plane because the signal, stimulated by non-resonant radiation, does not involve an excited state with a finite lifetime.

According to a second aspect of the invention, a solid support material 10 comprises at least one polymerase and at least one dipolar molecule positioned on or proximal to the polymerase.

According to a third aspect of the invention, an imaging system set up to detect a non-linear optical signal, comprises a solid support having immobilised thereon an enzyme that interacts with a polynucleotide, and a dipolar molecule 15 positioned on or proximal to the enzyme.

Description of the Drawings

The invention is described with reference to the accompanying figure, wherein:

Figure 1 is a schematic illustration of an imaging system that utilises 20 second harmonic generation; and

Figure 2 shows the second harmonic signal generated by a polymerase on incorporation of a specific polynucleotide.

Detailed Description of the Invention

The present invention makes use of conventional non-linear optical 25 measurements to identify a conformational and/or mass and/or energy distribution change occurring as a polynucleotide processive enzyme interacts with the individual bases on a target polynucleotide or incorporates nucleotides onto a nascent polynucleotide molecule.

The use of non-linear optical methods for imaging molecules is known. 30 What has not been appreciated is that these methods can be applied to the sequencing of a polynucleotide, making use of an immobilised or fixed enzyme.

In a separate embodiment, a linear signal is generated in addition to a non-linear signal and the linear signal is detected. The two signals are said to be coupled, resulting in enhanced detection.

The term "polynucleotide" as used herein is to be interpreted broadly, and includes DNA and RNA, including modified DNA and RNA, DNA/RNA hybrids, as well as other hybridising nucleic acid-like molecules, e.g. peptide nucleic acid (PNA).

The term "polynucleotide processive enzyme" as used herein is to be interpreted broadly and relates to any enzyme that interacts with a polynucleotide and moves continuously along the polynucleotide. The enzyme is preferably a polymerase enzyme, and may be of any known type. For example, the polymerase may be any DNA-dependent DNA polymerase. If the target polynucleotide is a RNA molecule, then the polymerase may be a RNA-dependent DNA polymerase, i.e. reverse transcriptase, or a RNA-dependent RNA polymerase, i.e. RNA replicase. In a preferred embodiment of the invention, the polymerase is T4 polymerase. In further preferred embodiments of the invention, the polymerase is either *E. coli* polymerase III holoenzyme (McHenry, Ann. Rev. Biochem., 1988; 57:519); T7 polymerase (Schwager *et al.*, Methods in Molecular and Cellular Biology, 1989/90; 1(4): 155-159) or bacteriophage T7 gene 5 polymerase complexed with *E. coli* Thioredoxin (Tabor *et al.*, J. Biol. Chem., 1987; 262: 1612-1623). Each of these polymerase enzymes binds to a target polynucleotide with high processivity (and fidelity) and therefore maintains a polymerase-polynucleotide complex, even when polymerisation is not actively taking place.

Alternative enzymes that interact with a polynucleotide include helicase, primase, holoenzyme, topoisomerase or gyrase enzymes. Such enzymes offer further advantages. For example, using a helicase reduces the problem of secondary structures that exist within polynucleotide molecules, as helicases encounter and overcome these structures within their natural environment. Secondly, helicases allow the necessary reactions to be carried out on double-stranded DNA at room temperature.

As the enzyme interacts with successive bases on the polynucleotide, its conformation will change depending on which base (or nucleotide) on the target it is brought into contact with. Thus, the temporal order of base pair additions during the reaction is measured on a single molecule of nucleic acid, i.e. the activity of the enzyme system on the template polynucleotide to be sequenced can be followed in real time. The sequence is deduced by identifying which base (nucleotide) is being incorporated into the growing complementary strand of the target polynucleotide via the catalytic activity of the enzyme.

An important aspect of the present invention is the immobilisation of the enzyme in a fixed position relative to the imaging system. This is preferably carried out by immobilising the enzyme to a solid support, with the enzyme retaining its biological activity. Methods for the immobilisation of suitable enzymes to a solid support are known. For example, WO-A-99/05315 describes the immobilisation of a polymerase enzyme to a solid support. General methods for immobilising proteins to supports are suitable.

The optical detection methods used in the present invention are intended to image at the single molecule level, i.e. to generate a distinct image/signal for one enzyme. A plurality of enzymes may be immobilised on a solid support at a density that permits single enzyme resolution. Therefore, in one embodiment, there are multiple enzymes immobilised on a solid support, and the method of the invention can be carried out on these simultaneously. This allows different polynucleotide molecules to be sequenced together.

It will be apparent to the skilled person to carry out the imaging method under conditions suitable to promote enzymic activity. For example, with regard to a polymerase enzyme, it will be apparent that the other components necessary for the polymerase reaction to proceed, are required. In this embodiment, a polynucleotide primer molecule and each of the nucleoside triphosphates dATP, dTTP, dCTP and dGTP, will be required. The nucleoside triphosphates may be added sequentially, with removal of non-bound nucleotides prior to the introduction of the next nucleoside triphosphate. Alternatively, all the triphosphates can be present at the same time. It may be preferable to utilise triphosphates that have one or more blocking groups which

can be removed selectively by pulsed monochromatic light, thereby preventing non-controlled incorporation. Suitable blocked triphosphates are disclosed in WO-A-99/05315.

High-resolution non-linear optical imaging systems are known in the art.

5 In general, the non-linear polarisation for a material can be expressed as:

$$P = X^{(1)}E^1 + X^{(2)}E^2 + X^{(3)}E^3 + \dots$$

where P is the induced polarisation, $X^{(n)}$ is the nth-order non-linear susceptibility,
10 and E is the electric field vector. The first term describes normal absorption and reflection of light; the second describes second harmonic generation (SHG), sum and difference frequency generation; and the third describes light scattering, stimulated Raman processes, third harmonic generation (TGH), and both two- and three-photon absorption.

15 A preferred imaging system of the present invention relies on the detection of the signal arising from second or third harmonic generation.

Single-molecule resolution using second or third harmonic generation (hereinafter referred to as SHG) is known in the art (Peleg *et al.*, Proc. Natl. Acad. Sci. USA, 1999; 95: 6700-6704 and Peleg *et al.*, Bioimaging, 1996; 4: 215-
20 224).

The general set-up of the imaging system can be as described in Peleg *et al.*, 1996, *supra*, and as shown in Figure 1. With reference to Figure 1, a laser (1) is used as the illumination source, to generate a laser beam which is then passed through a polarizer (2). Part of the laser beam may be directed through
25 a non-linear crystal (3) to produce a green beam to aid the alignment of the laser beam. A photodiode (4) is placed in close proximity to the optical path in order to provide a means to monitor the generated near-infrared (NIR) intensity. A filter (5) is positioned in front of the entrance port of a microscope to prevent any second harmonic from entering the microscope. The laser beam is focussed
30 onto the solid support comprising the immobilised enzyme, and the non-linear signal is collected by lenses (7) and detected using a monochromator (8). The fundamental intensity is blocked using an IR filter. The signal from the

photomultiplier is amplified, averaged and integrated using a boxcar averager and channel integrator (9). The generated signals are then transferred to a computer (10) to generate the images.

In order to generate the second or third harmonic, it is necessary to position an appropriate label on or in close proximity to the immobilised enzyme. Highly dipolar molecules are suitable for this purpose. (Lewis *et al.* Chem. Phys., 1999; 245: 133-144). An example of suitable molecules are dyes, particularly styryl dyes (such as membrane dye JPW 1259 – supplied by Molecular Probes). Green Fluorescent Protein (GFP) is another example of a "dye" or "label" which can be used to image via SHG. As used herein, GFP refers to both the wild-type protein, and spectrally shifted mutants thereof (Tsien, Ann. Rev. Biochem., 1998; 67:509 and US 5,777,079 and US 5,625,048). Other suitable dyes include di-4-ANEPPS, di-8-ANEPPS and JPW2080 (Molecular Probes).

The dipolar molecules may be located on the individual bases of the polynucleotide (or its complement if the dipolar molecules are attached to the nucleoside triphosphates and used in a polymerase reaction).

In a preferred embodiment of the invention, the enzyme, e.g. a polymerase, is prepared as a recombinant fusion with GFP. The GFP can be located at the N- or C- terminus of the enzyme (the C- terminus may be desirable if a polymerase is to be used in conjunction with a 'sliding clamp'). Alternatively, the GFP molecule can be located anywhere within the enzyme, provided that enzymic activity is retained.

In a separate embodiment of the present invention, the non-linear optical imaging system is Raman spectroscopy or surface enhanced Raman spectroscopy (SERS). An overview of Raman spectroscopy is contained in McGilp, Progress in Surface Science, 1995; 49(1): 1-106.

The optical radiation used to excite the Raman system is, preferably, Near Infrared Radiation (NIR). NIR excitation has the advantage of decreasing the fluorescence and Raman signal of the surrounding medium or solvent.

In a separate embodiment of the invention, the non-linear signal can be enhanced by the use of a metal nanoparticle and/or a roughened metal surface

(Boyed *et al.*, Phys Rev., 1984; B. 30: 519-526, Chen *et al.*, Phys. Rev. Lett., 1981; 46: 1010-1012 and Peleg *et al.*, 1996, *supra*). A signal enhancing metal nanoparticle can be conjugated to the enzyme (e.g. with a nanoparticle conjugated antibody, Lewis *et al.*, Proc. Natl. Acad. Sci. USA, 1999; 96: 6700-6704), immobilised near the immobilised/localised enzyme or brought into close proximity to the SHG dye/enzyme.

A metal nanoparticle enhances the spectroscopic imaging associated with, in particular, SHG from nanometric regions, thereby permitting improved imaging at the single molecule level. Spectroscopic imaging based on Raman scattering can also be improved using a metal nanoparticle. Suitable metal nanoparticles are known, and include gold and silver nanoparticles. The nanoparticles are generally of a diameter of from 5nm to 100nm, preferably from 10nm to 60nm. The nanoparticles can be attached to the polynucleotide (or its complement if the nanoparticles are attached to nucleoside triphosphates and used in a polymerase reaction).

A roughened metal surface has also been shown to improve the sensitivity of the SHG process (Chen *et al.*, 1981, *supra* and Peleg *et al.*, 1996, *supra*) and is also a requirement for SERS. The metal surface is usually silver or another noble metal. An initial selective modification of the metal surface at sub-wavelength spatial resolution can be carried out using various techniques, including the use of atomic force microscopy (AFM). A platinum-coated AFM tip can be used to catalyse hydrogenation of terminal azides to amino groups that are amenable to further derivatisation (Muller *et al.*, Science, 1995; 268: 272-273). The enzymes can then be placed into "hot spots" where high local fields exist in regions where optical modes are localised (Shalaev *et al.* Phys. Rep., 1996; 272:61).

In a separate embodiment of the invention, a nanoparticle can be brought into close proximity with the enzyme using an AFM cantilever tip/probe, to thereby enhance the non-linear signal.

AFM has been shown recently to be capable of having a time resolution and sensitivity applicable to the dynamic imaging of protein conformational changes (Rousso *et al.*, J. Struc. Biol., 1997; 119: 158-164). This is utilised in

a preferred embodiment of the invention, where an AFM probe/tip is positioned over the enzyme and, in combination with non-linear optical information (e.g. SHG), used to detect conformational changes of a protein due to the interaction between the enzyme and the nucleotide sequence as the enzyme moves along the target polynucleotide. The information may be collected in the far-field using conventional confocal optics or in reflection mode if used in conjunction with total internal reflection.

In a further embodiment, the non-linear signal (e.g. SHG) is monitored in the near-field using Near-Field Scanning Optical Microscopy (NSOM). NSOM is a form of scanning probe microscopy, which makes use of the optical interaction between a nanoscopic tip (as used in AFM) and a sample to obtain spatially resolved optical information. Near-field microscopy in combination with SHG has been studied extensively and shown to be surface sensitive on an atomic scale (McGilp, 1995, *supra*). The main advantage of using NSOM as part of the imaging system is that it allows a large increase in resolution to sub-wave-length dimensions. As the present invention relates to the conformational monitoring of a single enzyme, e.g. a polymerase enzyme, as it interacts with a polynucleotide, sub-wave-length spatial resolution is highly desirable. In the context of this aspect of the invention, it is preferable if an AFM cantilever tip is used as an apertureless Near-field scanning microscope (Sangohdar *et al*, J. Opt. A: Pure Appl. Opt., 1999; 523-530). This is analogous to the use of metallic nanoparticles as a source of local field enhancement. It is preferred that the tip is made out of, or coated with, a noble metal or any material which acts to increase the local electromagnetic field. Alternatively, a metallic nanoparticle may be connected directly to the cantilever tip. This has already been shown to be applicable to the monitoring of conformational changes at the single molecule level (Rousso, *et al. supra*).

In a further separate embodiment of the present invention, an independently generated surface plasmon (or polariton)/evanescent field can be used to enhance the signal-to-noise ratio of the non-linear signal. This evanescent wave enhanced imaging technique has greater signal-to-noise ratio than, for example, SHG imaging alone. In this embodiment, the evanescently

enhanced SHG field signal from the labelled enzyme can be collected in the near field by an NSOM fibre whilst simultaneously obtaining AFM conformational data, and at the same time the amount of absorbed evanescent radiation can be monitored to obtain information on the amount of coupling between the evanescent field and the labelled polymerase/SHG field.

In this configuration (NSOM collection mode) the system acts as a photon scanning tunnelling microscope (PSTM) and the evanescent or surface plasmon field is coupled into the NSOM fibre probe tip. Any attenuation in the field strength of the signal reaching the tip by the polymerase will be monitored via a detector positioned at the end of the tip.

Surface plasmon resonance is known in the art, and relies on the generation of an evanescent wave by applying an incident light beam to a prism. A typical set-up for use in this embodiment consists of a prism which is coupled optically to a metal coated glass coverslip on which an enzyme is immobilised. The coverslip is part of a microfluidic flow cell system with an inlet for introducing ligands (nucleotides) over the immobilised enzyme. The enzyme is also labelled to allow non-linear effects to be generated. An incident light beam is applied to the prism to generate the surface plasmon field. At the same time, a non-linear signal (e.g. second harmonic field) is generated by directing a pulsed near infrared laser through a polarizer and half wave plate, into an optical scanner for beam control via a filter to eliminate optical second harmonic noise, and then into the sample. The non-linear optical signal is collected with lenses and a filter and directed into a monochromator, passed to a photomultiplier tube for detection and then amplified and recorded via a computer system.

When the non-linear optical is coupled to that generating the evanescent field, the signal that is detected can also be the linear (evanescent) signal. In this embodiment, the NSOM can be used in the collection mode to detect the linear signal.

In a separate aspect of the present invention, the polynucleotide sequencing can be carried out within a cell.

It has been demonstrated that, in its native cellular environment, a DNA polymerase and its associated replisome complex is anchored in place (or

localised in space) within the cell (Newport *et al.*, Curr. Opin. Cell Biol., 1996; 8: 365; and Lemon *et al.*, Science, 1998; 282: 1516-1519. This native anchored replication complex is analogous to the immobilisation of the enzyme to a solid support.

5 This allows the *in vivo* monitoring of conformational and template sequence-related changes of replisome-related molecules at the single molecule level to be carried out in real-time during DNA replication and/or cell division.

 In order to carry out this aspect, it is necessary to modify the enzyme so that it can be imaged using nonlinear optical detection techniques. This can be
10 achieved by genetic fusion of the enzyme with, for example, green fluorescent protein (GFP). The cell should also be immobilised to permit detection to occur.

 The expressed fusion protein can be monitored/detected at its anchored cellular location via the application of non-linear optical detection (second harmonic generation).

15 The following Example illustrates the invention.

 In this experiment, a fusion protein of Green Fluorescent Protein (GFP) and a polymerase was created via recombinant techniques well known in the art.

 Quartz chips (14mm in diameter, 0.3mm thick) were spin-coated with a 50nm thick layer of gold and then coated with a layer of planar dextran. These
20 gold coated quartz chips were then placed into the fluid cell of a custom built Nearfield Scanning Optical Microscope (NSOM). The gold-coated quartz chips were coupled optically to a quartz prism via index matching oil. The fluid cell was then sealed and polymerase buffer was then allowed to flow over the chip.

 Immobilisation of the polymerase to the chip surface was carried out
25 according to Jonsson *et al.*, Biotechniques, 1991; 11:620-627. The chip environment was equilibrated with running buffer (10 mM hepes, 10mM MgCl₂, 150 mM NaCl, 0.05% surfactant P20, pH 7.4). Equal volumes of N-hydroxysuccinimide (0.1 M in water) and N-ethyl-N'-(dimethylaminopropyl) carbodimide (EDC) (0.1 M in water) were mixed together and injected across the
30 chip surface, to activate the carboxymethylated dextran. The polymerase-GFP fusion protein (150 µl) was mixed with 10mM sodium acetate (100 µl, pH 5) and injected across the activated surface. Finally, residual N-hydroxysuccinimide

esters on the chip surface were reacted with ethanolamine (35 μ l, 1 M in water, pH 8.5), and non-bound polymerase was washed from the surface. The immobilization procedure was performed with a continuous flow of running buffer (5 μ l/min) at a temperature of 25°C.

5 50 μ l of antibody binding buffer (10mM MES pH6.0, 150mM NaCl, 3mM EDTA) was flowed over the immobilized polymerase/GFP on the chip surface at a flow rate of 5 μ l/min at 25°C. A primary antibody (GFP (B-2)B biotin conjugated 200 μ l ml⁻¹, Santa Cruz Biotechnology) was diluted 1:3000 in antibody binding buffer and allowed to flow over the chip surface at a flow rate
10 of 5 μ l/min for 30 minutes. Excess antibody was then washed off the surface by flowing antibody binding buffer over the chip at a flow rate of 5 μ l/min for 30 minutes.

A secondary antibody (Immunogold conjugate EM Goat antimouse IgG (H+L) 40nm, British Biocell International) was diluted 1:1000 in antibody binding
15 buffer and allowed to flow over the chip surface at a flow rate of 5 μ l/min for 30 minutes. Excess antibody was then washed off the surface by flowing antibody binding buffer over the chip at a flow rate of 5 μ l/min for 30 minutes. The buffer was then returned to running buffer which was then allowed to flow over the chip at a rate of 5 μ l/min for 30 minutes before initiation of the next stage.

20 Two oligonucleotides were synthesized using standard phosphoramidite chemistry. The oligonucleotide defined as SEQ ID NO. 1 was used as the target polynucleotide, and the oligonucleotide defined as SEQ ID NO. 2 was used as the primer.

25 SEQ ID NO. 1

CAAGGAGAGGACGCTGCTTGTCGAAGGTAAGGAACGGACGAGAGAAGGGAGAG

SEQ ID NO.2

30

CTCTCCCTTCTCTCGTC

The two oligonucleotides were reacted under hybridizing conditions to form the target-primer complex. The primed DNA was then suspended in buffer (20 mM Tris-HCl, pH 7.5, 8 mM MgCl₂, 4% (v/v) glycerol, 5 mM dithiothreitol (DDT) containing 150 µl of the β sub-units that form a sliding-clamp complex around the primer DNA. This process is known as pre-initiation.

In order to detect the conformational changes in the polymerase, a modified NSOM was used in tapping mode, with pulled quartz multimode 100µm long fibre cantilevers. The cantilever was driven close to its resonant frequency and an initial area scan was carried out over the surface of the chip containing immobilized antibodies. The second harmonic signal was generated from the immobilized polymerase in the flow cell via initial illumination from a pulsed Near infra-red laser source. The NSOM tip was then scanned over the chip surface in the flow cell in order to obtain an image of a 40nm gold particles in the flow cell which is associated with the polymerase. The tip is then held in stationary mode over the polymerase.

The pre-initiated pre-primed complex was then injected into the flow cell at a flow rate of 5 µl/min so that the "clamp" around the primer-template molecule forms a complex with the immobilized polymerase. The flow cell was maintained at 25°C by a cooling device built into the flow cell.

The running buffer was then flushed continuously through the flowcell at 500 µl/min. After 10 minutes the sequencing reaction was initiated by injection of 0.4mM dATP (8 µl) into the buffer at a flow rate of 500 µl/min. After 4 minutes 0.4mM dTTP (8 µl) was injected into the flowcell. Then after another 4 minutes 0.4mM dGTP (8 µl) was injected and after another 4 minutes 0.4mM dCTP (8 µl) was injected. This cycle was then repeated 10 times. Over the entire time period the second harmonic signal transmitted via the multimode fibre was passed into a monochromator and then into a photomultiplier. The signal from the photomultiplier was then amplified and fed into a computer for processing and storage.

The intensity change of second harmonic signal arising from the polymerase complex for a period of 10 seconds from the start of each injection was then calculated and plotted against nucleotide injected into the flow cell.

The results of the sequencing reaction are shown in Figure 2. As can be seen from the graph, large intensity changes (larger intensity changes accounting for identical nucleotides adjacent to each other) correspond to the complement of that of SEQ ID NO. 1 (reading from right to left, minus that part of which
5 hybridizes to the primer sequence).

CLAIMS

1. A method for determining the sequence of a polynucleotide, comprising the steps of:
 - (i) contacting a polynucleotide processive enzyme immobilised in a fixed position, with a target polynucleotide under conditions sufficient to induce enzyme activity;
 - (ii) detecting an effect consequent on the interaction of the enzyme and polynucleotide,wherein the effect is detected by measurement of a non-linear optical signal or a linear signal coupled to a non-linear signal.
2. A method according to claim 1, wherein the effect is detected by measurement of a non-linear signal.
3. A method according to claim 1 or claim 2, wherein the non-linear optical detection is second or third harmonic generation imaging.
4. A method according to claim 1 or claim 2, wherein the non-linear optical detection is Raman spectroscopy or surface enhanced Raman spectroscopy.
5. A method according to any preceding claim, wherein a dipolar molecule is positioned on or proximal to the enzyme.
6. A method according to claim 5, wherein the molecule is a styryl dye molecule.
7. A method according to claim 5, wherein the molecule is green fluorescent protein.
8. A method according to claim 5 or claim 6, wherein the dipolar molecule is attached to the individual bases of the polynucleotide.
9. A method according to any preceding claim, wherein the enzyme is a polymerase.
10. A method according to any of claims 1 to 8, wherein the enzyme is a helicase or primase enzyme.
11. A method according to claim 10, wherein step (i) comprises the addition of the nucleoside triphosphates dATP, dTTP, dGTP and dCTP.
12. A method according to claim 11, wherein the nucleoside triphosphates comprise one or more blocking groups which can be removed selectively by

pulsed monochromatic light.

13. A method according to any preceding claim, wherein a metal nanoparticle is positioned on or proximal to the enzyme.

14. A method according to claim 13, wherein the nanoparticle is a gold or
5 silver nanoparticle.

15. A method according to claim 13 or claim 14, wherein the nanoparticle is incorporated onto one or more of the individual bases of the polynucleotide.

16. A method according to any preceding claim, wherein the enzyme is immobilised on a solid support.

10 17. A method according to claim 16, wherein there are a plurality of enzymes immobilised on the solid support.

18. A method according to claim 16 or claim 17, wherein the solid support has a roughened metal surface.

19. A method according to any of claims 16 to 18, wherein the support is
15 silver or gold.

20. A method according to any preceding claim, wherein detection is carried out in conjunction with Atomic Force Microscopy or Near-Field Scanning Optical Microscopy.

21. A method according to any preceding claim, further comprising the
20 application of localised surface plasmon resonance.

22. A method according to any of claims 1 to 14, wherein the enzyme is immobilised in a fixed position within a cell.

23. A solid support material, comprising at least one immobilised polymerase and at least one dipolar molecule positioned on or proximal to the polymerase.

24. A solid support material, comprising a cell immobilised thereon, wherein
25 the cell comprises a polymerase enzyme maintained in an fixed position within the cell.

25. An imaging system set up to detect a non-linear optical signal, comprising a solid support having immobilised thereon an enzyme that interacts with a
30 polynucleotide, and a dipolar molecule positioned on or proximal to the enzyme.

1/2




Figure 1

2/2




Figure 2

SEQUENCE LISTING

<110> Medical Biosystems Ltd.

<120> POLYNUCLEOTIDE SEQUENCING METHOD

<130> REP06729WO

<140> (not yet known)

<141> 2002-05-20

<150> 0112238.1

<151> 2001-05-18

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1

caaggagagg acgctgcttg tcgaaggtaa ggaacggacg agagaaggga gag 53

<210> 2

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 2

ctctcccttc tctcgtc 17

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/095070 A3

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/GB02/02345

(22) International Filing Date: 20 May 2002 (20.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0112238.1 18 May 2001 (18.05.2001) GB

(71) Applicant (*for all designated States except US*): MEDICAL BIOSYSTEMS LTD. [GB/GB]; The Old Mill, Beaston Cross, Broadhempston, Nr- Totnes, Devon TQ9 6BX (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): DENSHAM, Daniel, Henry [GB/GB]; The Old Mill, Beaston Cross, Broadhempston, Nr- Totnes, Devon TQ9 6BX (GB).

(74) Agent: JAPPY, John, William, Graham; Gill Jennings & Every, Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
18 September 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: POLYNUCLEOTIDE SEQUENCING METHOD

(57) Abstract: A method for determining the sequence of a polynucleotide comprising the steps of (i) contacting a polynucleotide processive enzyme immobilised in a fixed position, with a target polynucleotide under conditions sufficient to induce enzyme activity; (ii) detecting an effect consequent on the interaction of the enzyme and the polynucleotide, wherein the effect is detected by measurement of a non-linear optical signal or a linear signal coupled to a non-linear signal.



WO 02/095070 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02345

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 53805 A (ARMES NIAL ANTONY ;STEMPLE DEREK LYLE (GB); ASM SCIENT INC (US)) 14 September 2000 (2000-09-14)	1-7,9, 13-17, 19,21, 23,25
Y	abstract page 3, paragraph 3 -page 4, paragraph 3 page 14, paragraph 1 -page 19, paragraph 2 claims 1-23 --- -/--	8,10-12, 18,20, 22,24

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

31 July 2003

Date of mailing of the international search report

12/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Madlener, M

INTERNATIONAL SEARCH REPORT

Inte bnal Application No

PCT/GB 02/02345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 01 16375 A (RUBENS DENISE ;US HEALTH (US); SCHNEIDER THOMAS D (US)) 8 March 2001 (2001-03-08) abstract page 3, line 36 -page 6, line 39 examples 1,2,4 figures 1,2 claims 1-45 ---	1,2,5-7, 9,16,17, 20,23,25 3,4,8, 10-15, 18,19, 21,22,24
X Y	WO 00 70073 A (CORNELL RES FOUNDATION INC) 23 November 2000 (2000-11-23) abstract page 5, line 11 -page 7, line 23 page 18, line 7 -page 18, line 32 page 29, line 22 -page 32, line 24 claims 1-61 figure 1C ---	1-4,9, 13,14, 16,17, 19,20, 23,25 5-8, 10-12, 15,18, 21,22,24
X Y	WO 01 25480 A (DENSHAM DANIEL HENRY ;MEDICAL BIOSYSTEMS LTD (GB)) 12 April 2001 (2001-04-12) abstract page 3, line 10 -page 5, line 19 page 8, line 33 -page 9, line 33 claims 1-21 ---	1,2,5-7, 9,16,17, 23,25 3,4,8, 10-15, 18-22,24
X Y	WO 99 05315 A (DENSHAM DANIEL HENRY ;MEDICAL BIOSYSTEMS LTD (GB)) 4 February 1999 (1999-02-04) cited in the application abstract page 2, line 26 -page 3, line 24 page 4, line 10 -page 6, line 2 claims 1-29 ---	1,2,9, 16,17 3-8, 10-15, 18-25

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 95 06138 A (UNIV CALIFORNIA) 2 March 1995 (1995-03-02) abstract page 3, last paragraph -page 6 page 10, last paragraph -page 14 claims 12-19	1,2,9, 16,17 3-8, 10-15, 18-25
X Y	WO 00 60114 A (DENSHAM DANIEL HENRY ;MEDICAL BIOSYSTEMS LTD (GB)) 12 October 2000 (2000-10-12) abstract page 1, line 9 -page 1, line 33 claims 1-6	1,2,10, 16,17 3-9, 11-15, 18-25
X Y Y	LEMON KATHERINE P ET AL: "Localization of bacterial DNA polymerase: Evidence for a factory model of replication." SCIENCE (WASHINGTON D C), vol. 282, no. 5393, 20 November 1998 (1998-11-20), pages 1516-1519, XP002248280 ISSN: 0036-8075 cited in the application the whole document - in particular Fig. 1 in combination with the summary of ref. 6 (p. 1519, left col.)	24 22
Y	EP 0 740 156 A (POLYTECH TRANSFER LTD) 30 October 1996 (1996-10-30) claims 1-7 column 5, line 41 -column 6, line 2 column 4, line 23 -column 4, line 49 column 2, line 27 -column 3, line 55 column 1, line 5 -column 1, line 16 abstract	1-25
Y	WO 01 23459 A (ARRAY BIOSCIENCE CORP) 5 April 2001 (2001-04-05) abstract page 9, line 24 -page 12, line 7 page 54, line 13 -page 54, line 18 claims 1-64	1-25
Y	WO 00 36152 A (WILLIAMS JOHN G K ;LI COR INC (US)) 22 June 2000 (2000-06-22) abstract page 2, line 28 -page 4, line 12 claims 1-30	1-25
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 958 696 A (CRUTE JAMES J) 28 September 1999 (1999-09-28) abstract column 2, line 3 - line 35 claims 1-10 ---	10-12
Y	JENKINS R H ET AL: "A novel Raman spectrophotometric method for quantitative measurement of nucleoside triphosphate hydrolysis." BIOSPECTROSCOPY, vol. 5, no. 1, 1999, pages 3-8, XP009014146 ISSN: 1075-4261 the whole document ---	1-25
Y	CAMPAGNOLA PAUL J ET AL: "High-resolution nonlinear optical imaging of live cells by second harmonic generation." BIOPHYSICAL JOURNAL, vol. 77, no. 6, December 1999 (1999-12), pages 3341-3349, XP002248209 ISSN: 0006-3495 the whole document ---	1-25
Y	PELEG G ET AL. : "Gigantic optical non-linearities from nanoparticle-enhanced molecular probes with potential for selectively imaging the structure and physiology of nanometric regions in cellular systems" BIOIMAGING, vol. 4, 1996, pages 215-224, XP001118469 cited in the application the whole document ---	1-25
A	WO 99 44045 A (MASSACHUSETTS INST TECHNOLOGY) 2 September 1999 (1999-09-02) page 3, line 19 -page 5, line 26 abstract ---	1-25
A	PELEG G ET AL: "Nonlinear optical measurement of membrane potential around single molecules at selected cellular sites." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 8 JUN 1999, vol. 96, no. 12, 8 June 1999 (1999-06-08), pages 6700-6704, XP002248210 ISSN: 0027-8424 the whole document ---	1-25

-/--

INTERNATIONAL SEARCH REPORT

Int ional Application No
PCT/GB 02/02345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LEWIS A ET AL. : "Second-harmonic generation of biological interfaces: probing the membrane protein bacteriorhodopsin and imaging membrane potential around GFP molecules at specific sites in neuronal cells of <i>C. elegans</i> " CHEMICAL PHYSICS, vol. 245, 1999, pages 133-144, XP002248211 cited in the application abstract ---	1-25
A	SCHULTZ S ET AL: "Single-target molecule detection with nonbleaching multicolor optical immunolabels" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 3, 1 February 2000 (2000-02-01), pages 996-1001, XP002227348 ISSN: 0027-8424 the whole document ---	1-25
A	PUPPELS G J ET AL: "CONFOCAL RAMAN MICROSCOPY IN BIOLOGY: APPLICATIONS AND FUTURE DEVELOPMENTS" TRAC, TRENDS IN ANALYTICAL CHEMISTRY, ANALYTICAL CHEMISTRY. CAMBRIDGE, GB, vol. 10, no. 8, 1 September 1991 (1991-09-01), pages 249-253, XP000219626 ISSN: 0165-9936 the whole document ---	1-25
A	NIE S ET AL. : "Probing Single Molecules and Single Nanoparticles by Surface-Enhanced Raman Scattering" SCIENCE, vol. 275, 21 February 1997 (1997-02-21), pages 1102-1106, XP002248212 the whole document ---	1-25
A	HA T ET AL: "Probing the interaction between two single molecules: Fluorescence resonance energy transfer between a single donor and a single acceptor" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 13, 1996, pages 6264-6268, XP002171249 ISSN: 0027-8424 the whole document ---	1-25
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02345

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MCGILP J F: "A REVIEW OF OPTICAL SECOND-HARMONIC AND SUM-FREQUENCY GENERATION AT SURFACES AND INTERFACES" JOURNAL OF PHYSICS D. APPLIED PHYSICS, IOP PUBLISHING, BRISTOL, GB, vol. 29, no. 7, 14 July 1996 (1996-07-14), pages 1812-1821, XP000621099 ISSN: 0022-3727 the whole document</p>	1-25

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/02345

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0053805	A	14-09-2000	AU 3174600 A CA 2366112 A1 EP 1159453 A1 WO 0053805 A1 JP 2002537858 A	28-09-2000 14-09-2000 05-12-2001 14-09-2000 12-11-2002
WO 0116375	A	08-03-2001	AU 7086800 A WO 0116375 A2	26-03-2001 08-03-2001
WO 0070073	A	23-11-2000	AU 5027600 A CA 2373385 A1 EP 1179085 A1 JP 2002543847 T WO 0070073 A1 US 2003044781 A1 US 2003092005 A1	05-12-2000 23-11-2000 13-02-2002 24-12-2002 23-11-2000 06-03-2003 15-05-2003
WO 0125480	A	12-04-2001	AU 7546700 A BR 0014468 A CA 2386115 A1 CN 1391615 T EP 1226271 A2 WO 0125480 A2 JP 2003511043 T	10-05-2001 20-08-2002 12-04-2001 15-01-2003 31-07-2002 12-04-2001 25-03-2003
WO 9905315	A	04-02-1999	AT 225858 T AU 735898 B2 AU 8455998 A BR 9812270 A CN 1265158 T DE 69808661 D1 DE 69808661 T2 DK 1017848 T3 EP 1229133 A2 EP 1017848 A2 ES 2183394 T3 WO 9905315 A2 JP 2001511358 T NZ 502557 A NZ 515315 A PT 1017848 T RU 2198221 C2	15-10-2002 19-07-2001 16-02-1999 18-07-2000 30-08-2000 14-11-2002 31-07-2003 10-02-2003 07-08-2002 12-07-2000 16-03-2003 04-02-1999 14-08-2001 01-02-2002 30-06-2003 28-02-2003 10-02-2003
WO 9506138	A	02-03-1995	WO 9506138 A1 US 5620854 A	02-03-1995 15-04-1997
WO 0060114	A	12-10-2000	AU 3978100 A BR 0009529 A CA 2367277 A1 CN 1345379 T EP 1198590 A2 WO 0060114 A2 JP 2002540800 T	23-10-2000 29-01-2002 12-10-2000 17-04-2002 24-04-2002 12-10-2000 03-12-2002
EP 0740156	A	30-10-1996	CA 2174360 A1 DE 69615254 D1 EP 0740156 A1 JP 8320322 A	28-10-1996 25-10-2001 30-10-1996 03-12-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/02345

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0123459	A	05-04-2001	AU 7616100 A	30-04-2001
			AU 7714800 A	30-04-2001
			AU 7716500 A	30-04-2001
			EP 1221047 A1	10-07-2002
			EP 1222432 A1	17-07-2002
			EP 1242510 A1	25-09-2002
			JP 2003510065 T	18-03-2003
			JP 2003510552 T	18-03-2003
			JP 2003510607 T	18-03-2003
			TW 445362 B	11-07-2001
			WO 0123822 A1	05-04-2001
			WO 0123459 A1	05-04-2001
			WO 0123888 A1	05-04-2001
			US 2001053521 A1	20-12-2001
			US 2002132371 A1	19-09-2002
			US 2001054495 A1	27-12-2001
WO 0036152	A	22-06-2000	AU 2180200 A	03-07-2000
			AU 2360200 A	03-07-2000
			CA 2355816 A1	22-06-2000
			EP 1141409 A1	10-10-2001
			JP 2002532104 T	02-10-2002
			WO 0036151 A1	22-06-2000
			WO 0036152 A1	22-06-2000
			US 6255083 B1	03-07-2001
			US 6232075 B1	15-05-2001
			US 2001018184 A1	30-08-2001
			US 2002115076 A1	22-08-2002
US 5958696	A	28-09-1999	NONE	
WO 9944045	A	02-09-1999	US 2002150938 A1	17-10-2002
			WO 9944045 A1	02-09-1999